Daré Bioscience (DARE)
Develops women's-health products spanning contraception, sexual health, menopause and vaginal health.
Something off on this page? Send us feedback.
Develops and commercializes women's-health products through direct sales, compounded prescriptions, partnerships and grant-funded development. Its portfolio spans marketed and clinical-stage products, while most therapeutic candidates remain dependent on trials, regulatory review and external commercialization.
Develops women's-health pharmaceuticals and delivery technologies across contraception, sexual health, vaginal health, menopause, fertility and infectious disease. The portfolio is assembled through licenses, acquisitions and collaborations, then advanced with external clinical and manufacturing providers.
XACIATO, a single-dose treatment for bacterial vaginosis, is FDA approved and commercialized by Organon. Flora Sync LF5 is sold directly through the DARE Health Hub, while DARE to PLAY Sildenafil Cream uses a cash-pay compounded-prescription model. Ovaprene, a hormone-free monthly intravaginal contraceptive candidate, remains in a pivotal trial.
Operates primarily in the United States, with an Australian subsidiary used for early clinical studies and certain worldwide rights under license. Progress depends on clinical and regulatory results, funding awards, outside service providers and commercial partners; Organon controls XACIATO marketing, distribution and sales.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Sep 4, 2025 | Maxim Group | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.6M · Total debt $6.8M · Total assets $22.4M · Shareholders' equity −$560.1K
- Revenue
- $187.5K
- Operating income
- −$3.0M
- Net income
- −$3.0M
No dividends on record.
| Institutions24 holders · as of Mar 31, 2026 | 6.70% | 1.02M shares | |
| Insiders5 holders · as of Jul 2, 2026 | 1.09% | 167.4K shares | |
| Otherremainder | 92.21% | 14.10M shares |
15.29M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 3.02% | 462,305 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.16% | 177,839 | 13Fas of Mar 31, 2026 |
US Bancorp \DE\Institution | 0.60% | 91,370 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.43% | 65,938 | 13Fas of Mar 31, 2026 |
Robin Joan SteeleInsiderdirector | 0.31% | 47,055 | Form 4filed Jul 2, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Organon
Nexplanon and NuvaRing contest monthly and long-acting contraception.
- CooperCompanies
Paragard is a major hormone-free contraception alternative.
- Pfizer
Established systemic and vaginal menopause-therapy alternatives.
- Perrigo
OTC Opill provides a low-friction contraceptive alternative.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Daré Bioscience | $0.7430 | −3.53% | $11.1M | — | — | 8.1 | — |
| Organon | $13.76 | −0.15% | $3.62B | 17.9 | 3.9 | 0.6 | −2.3% |
| CooperCompanies | $70.21 | +0.67% | $13.60B | 59.1 | 14.7 | 3.2 | +7.9% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Perrigo | $14.05 | −2.97% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Median | 38.3 | 8.2 | 1.6 | +0.2% |